Standout Papers

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons... 2018 2026 2020 2023 313
  1. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) (2018)
    Young Kwang Chae, Ayush Arya et al. Journal for ImmunoTherapy of Cancer

Immediate Impact

9 from Science/Nature 61 standout
Sub-graph 1 of 24

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
2 intermediate papers

Works of Ayush Arya being referenced

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
2018 Standout

Author Peers

Author Last Decade Papers Cites
Ayush Arya 318 109 288 150 4 576
Matthew Winans 243 47 273 207 7 622
Stephanie J. McAlhany 249 246 400 94 8 734
Natanya R. Kerper 345 72 223 312 4 654
Tianjian Lu 327 67 216 166 5 628
Manuela Migliavacca 451 83 299 163 10 720
Almudena Santos 434 61 272 323 6 717
Caroline Contat 159 76 369 213 5 684
Nina Sausgruber 145 103 473 144 9 700
Paola Bianca 315 99 329 114 6 617
Marina Ichetovkin 201 110 316 42 6 625

All Works

Loading papers...

Rankless by CCL
2026